Skip to main content
Premium Trial:

Request an Annual Quote

Tarif Awad, Timm Jessen, William Molnar, Chris van Ingen, Thomas Mino, Joseph Vallner

Tarif Awad has been named director of external scientific collaborations at VisEn Medical, the Woburn, Mass.-based firm said last week.
He joins VisEn from Affymetrix, where he was senior manager of pharmaceutical and industrial collaborations.
Awad holds a BSc from the University of California, Irvine, and a PhD in zoology from the University of Washington.

Timm Jessen has joined Scienion’s supervisory board following an election at the company’s recent general shareholders’ meeting.
He previously served as chief scientific officer of Evotec for several years and held various positions at Hoechst, later Sanofi-Aventis.

Agilent Technologies said last week that William Molnar has joined the company as vice president and general manager of its Stratagene division, which it acquired June 7.
Molnar most recently served as vice president and general manager of EMD Chemicals’ lab business where he led the merger of the biosciences and lab chemical businesses.
He holds an MBA in finance and industrial marketing from LoyolaCollege, a master’s degree in chemical engineering from Carnegie Mellon University, and a bachelor’s degree in chemistry from BethanyCollege.
Agilent Technologies also said last month that Chris van Ingen, president of the Bio-Analytical Measurement business, will retire on Oct. 31, the last day of Agilent's fiscal year.
Van Ingen, 61, is a 30-year veteran of Agilent and Hewlett-Packard, which spun off Agilent in November 1999. He was appointed to his current position in May 2001.
Agilent did not say who will run the Bio-Analytical Measurement business beginning Nov. 1.

Lumera said last month that Thomas Mino has resigned as CEO and from his post on the company’s board of directors. Mino will continue to serve Lumera in a consulting capacity, the company said.
Lumera’s board has formed a search committee to find a new CEO. Until then, current board member Joseph Vallner will step in as president and interim CEO.
Vallner also recently was named CEO of Lumera’s newly created proteomics subsidiary Plexera.
Lumera also announced last month that it had entered into a “severance and consulting” agreement with Mino.
Under the terms of the agreement, which went into effect Aug. 20, Mino is entitled to receive, “in addition to amounts currently due to him for work performed and vacation days accrued prior to his resignation, an amount equal to his current annual salary, $200,000 of which is payable in a single lump sum immediately and the remainder of which is payable in equal installments over the next 12 months.”
Lumera will also “continue to contribute to the premium cost of coverage” of Mino and his dependents under Lumera's medical and dental plans during the next 12 months at the same rate as Lumera contributes to the cost of coverage for active employees.
In addition, Mino will serve as a consultant to Lumera for up to 20 hours per month for an initial period of 10 months that begin Sept. 1. In exchange, Mino will be paid $10,000 per month during the initial 10-month period and will receive no compensation for any consulting services thereafter.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.